Oyanalytika Inc., founded in 2021, is a woman-owned consultancy specializing in data analytics for clinical research and development. Based in Frederick, Maryland, this innovative firm provides expert services in designing, analyzing, and interpreting clinical studies, with a particular emphasis on regulatory support. Their team is experienced in handling complex clinical and pre-clinical studies, making them a vital resource for data safety monitoring committees and institutional review boards.

Oyanalytika's primary focus centers on studies related to COVID-19 vaccines and therapeutics, employing cutting-edge solutions to address emerging variants. The company's founders, Dr. Ena M. Bromley and Dr. Gene Olinger, boast extensive backgrounds in oncology, infectious diseases, and translational research, and have been instrumental in developing various therapeutic and vaccine solutions.

With expertise in high-dimensional analytics, Oyanalytika aims to bridge complex data with clinical relevance, ensuring effective communication and interpretation of findings across diverse disease modalities. Their commitment to advancing healthcare underscores their mission to enhance patient outcomes through informed research and analytics.